AI is advancing our understanding of the complexities of age-related macular degeneration, according to a presenter.

Panelists discuss how aflibercept’s structural design and the higher molar dose of its 8-mg formulation enhance VEGF binding, treatment durability, and clinical predictability.

Panelists discuss how faricimab’s dual VEGF-A and Ang-2 inhibition may offer vascular stability advantages over single-pathway blockade, despite ongoing questions about Ang-2’s independent therapeutic ...

In this video from the American Academy of Ophthalmology meeting, Jennifer I. Lim, MD, MBA, discusses three gene therapies currently being studied for the treatment of age-related macular degeneration ...

Australian researchers have for the first time pinpointed specific genetic changes that increase the risk of severe, ...

Anti-VEGF therapy for patients with retinopathy of prematurity reduces myopia compared with laser treatments, but comes with other risks.